Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

Obesity : Preventing and managing the global epidemic

D. S. Akram, Arne Astrup, Tola Atinmo et al. · Research at the University of Copenhagen (University of Copenhagen) · 2000 · 13K citations

Public Health, Preventive Medicine, Public Health Nutrition +12

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Helen B. Hubert, M Feinleib, Patricia McNamara et al. · Circulation · 1983 · 4.3K citations · Full text

Medicine, Cardiology, Epidemiology +16

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Luc F. Van Gaal, Aila Rissanen, André Scheen et al. · The Lancet · 2005 · 1.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

Lars Sjöström, Aila Rissanen, Teis Andersen et al. · The Lancet · 1998 · 1.2K citations

Agriculture, Nutrition, Nutritional Sciences +14

Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat

Michael Davidson, Jonathan Hauptman, Mario DiGirolamo et al. · JAMA · 1999 · 945 citations

Agriculture, Pharmacology, Pharmacotherapy +17